Obesity drug makers chase $100bn global market

Novo Nordisk's weekly injection Wegovy, known as Ozempic when used for diabetes, was approved in 2021.

Drug developers are chasing an obesity drug gold rush that may be worth up to $100bn by rolling out treatments that can help lose as much as 24% of weight in less than a year.

The success of these treatments, especially from companies such as Novo Nordisk and Eli Lilly, has attracted the attention of celebrities, including Tesla chief executive Elon Musk and former British prime minister Boris Johnson.